Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.

Size: px
Start display at page:

Download "Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines."

Transcription

1 Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler therapy, choice of treatment is based on assessment of inhaler technique and patient preference. Treatment options are listed in order of preference. The guidelines below assume that any inhaler can be successfully used. Initial treatment Either a short-acting beta agonist (SABA) or a short acting muscarinic antagonist (SAMA) should be given as required SABA choice Salbutamol Terbutaline SAMA choice Ipratropium 20microg 2 puffs qds prn For patients with FEV1 >50% predicted with zero to one exacerbation(s) requiring antibiotics and / or steroids within the last 12 months at presentation Choose either a

2 Long acting Beta Agonist (LABA) OR Long-acting Muscarinic Antagonist (LAMA) LABA choice 1. Formoterol 12 micrograms (one puff twice daily) 2. Indacaterol 150microg Breezhaler (one puff once daily) 3. Salmeterol 50 micrograms twice daily (either two puffs twice daily or one blister twice daily) LAMA choice 1. Tiotropium 18 micrograms handihaler (one inhalation once daily) 2. Aclidinium 400micrograms Genuair (one puff twice daily) 3. Glycopyronnium 50micrograms Breezhaler (one puff once daily) 4. Tiotropium 2.5 micrograms Respimat (two puffs once daily). Please note, respimat should only be used where no other inhaler device is appropriate. For patients with FEV1 >50% predicted with more than one exacerbation requiring antibiotics and / or steroids within last 12 months at presentation Choose Tiotropium 18 microgram handihaler (one inhalation once daily)

3 For patients with FEV1 > 50% predicted who are on either a LABA or a LAMA who continue to have symptoms but have had zero or one exacerbations requiring antibiotics and / or steroids Give LAMA PLUS LABA Anoro (vilanterol / umeclidinium) via Ellipta device one puff once daily Or use individual components as listed above. Consider once or twice daily dosing issues with both inhalers as well as technique. For patients with FEV1 > 50% predicted who continue to have symptoms (or exacerbations) despite regular treatment with a LABA + LAMA Discontinue LABA (but continue LAMA) AND ADD LABA/ICS (Long-acting beta agonist / Inhaled Corticosteroid) 1. Symbicort 400/12 turbohaler (one puff twice daily) or Symbicort 200/6 turbohaler (two puffs twice daily) 2. Seretide 500 accuhaler (one puff twice daily) or Relvar Ellipta 92/22 microg (one puff ONCE daily) 3. Fostair 100/6 MDI inhaler (two puffs twice daily) if a MDI is necessary *Note Seretide 250 evohaler is not licensed for COPD. Use Fostair instead of Seretide 250 evohaler. For relative costings see table below

4 *Note Relvar Ellipta 92/22microg is a new product to market containing a potent steroid equivalent to 250mcg fluticasone propionate twice daily *All inhaled corticosteroids carry a small, but significant risk of pneumonia SAFETY INFORMATION Relvar Ellipta is packaged in a pale blue livery which may be confused with a salbutamol inhaler. The patient must be explicitly informed that this inhaler is not to be used more than once a day because it contains a potent steroid. For patients with FEV1 <50% predicted with or without exacerbations Choose LAMA 1. Tiotropium 18microgram handihaler (one puff once daily) 2. Aclidinium 400microgram Genuair (one puff twice daily) 3. Glycopyronnium 50microgram Breezhaler (one puff once daily) For patients with FEV1 <50% predicted who continue to be symptomatic after a 3 month trial of LAMA Add LABA/ICS 1. Symbicort 400/12 turbohaler (one puff twice daily) or Symbicort 200/6 turbohaler (two puffs twice daily) 2. Seretide 500 accuhaler (one puff twice daily) or Relvar Ellipta 92/22 microg (one puff once daily) 3. Fostair 100/6 MDI (two puffs twice daily)

5 Inhaler / device Cost (BNF Feb 2014) Tiotropium handihaler Aclidinium Genuair Glycopyrronium Breezhaler Formoterol Indacaterol Breezhaler Salmeterol 25 MDI Tiotropium Respimat Relvar Ellipta 92/ Symbicort 200/6 turbohaler Symbicort 400/12 turbohaler Seretide 500 accuhaler Seretide 250 evohaler Flutiform 250 MDI Fostair 100/6 MDI Review For secondary care, patients under the care of a respiratory consultant should be reviewed in outpatients clinic at appropriate intervals until such time that the patient is discharged from clinic to be managed in primary care. For primary care, it is suggested that the patient is reviewed annually to ensure inhaler technique / adherence is satisfactory and the patient is benefiting from continued treatment. Review should be more frequent if the patient exacerbates or continues to experience ongoing symptoms of breathlessness etc with the option to refer into the care of a respiratory consultant where appropriate. Community pharmacists should check inhaler technique after every change of device.

6

COPD Prescribing Guidelines

COPD Prescribing Guidelines South Staffordshire Area Prescribing Group COPD Prescribing Guidelines Inhaler choices in this guideline are different from previous versions produced by the APG. It is not expected patients controlled

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 3.2: Corticosteroids Beclometasone 50, 100 and 250micrograms/dose Clickhaler Clenil Modulite (Beclometasone CFC free) 50, 100, and 250micrograms/dose MDI

More information

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting

More information

COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways

COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways COPD RESOURCE PCK SECTION 11 Fife Integrated COPD Care Pathways In this section: 1. COPD Guidance treatment at each stage of the disease 2. Overview of Respiratory (COPD) Integrated Pathway 3. Chronic

More information

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency

More information

GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY

GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY Preferred Anticholinergics and Combinations Atrovent HFA (ipratropium) Combivent Respimat (ipratropium/albuterol) Ipratropium neb inhalation

More information

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families

More information

medicineupdate to find out more about this medicine

medicineupdate to find out more about this medicine medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition

More information

Highlights for COPD Management

Highlights for COPD Management COPD NEW DRUGS, NEW DEVICES AND CONSIDERATIONS FOR BEST PRACTICE September 2015 INSIDE Pg 2: COPD Overview - a birds eye view Pg 3: COPD Pharmacotherapy Comparison Chart - sorting out all the medication

More information

Bronchodilators in COPD

Bronchodilators in COPD TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for

More information

Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Topic: New Treatment = Better Outcome?

Topic: New Treatment = Better Outcome? Session on COPD: Novel Concepts and Promising New Drugs Topic: New Treatment = Better Outcome? Through a CME Grant sponsored by New Treatment = Better Outcome? Tim S. Trinidad, MD Disclosure Present: COPD

More information

Post-market review of COPD medicines. Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ)

Post-market review of COPD medicines. Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ) Post-market review of COPD medicines Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ) EXECUTIVE SUMMARY With the addition of new medicines

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD

More information

AECOPD: Management and Prevention

AECOPD: Management and Prevention AECOPD: Management and Prevention Neil MacIntyre MD Duke University Medical Center Durham NC AECOPD: Management and Prevention AECOPD: Definitions and impact Acute management of AECOPD Preventing AECOPD.

More information

Pathway for Diagnosing COPD

Pathway for Diagnosing COPD Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

Kortverk. betaagonist. Grönmarkerat är rekommenderat i första hand vid KOL resp astma för vuxna och barn >7år. Antikolinergika.

Kortverk. betaagonist. Grönmarkerat är rekommenderat i första hand vid KOL resp astma för vuxna och barn >7år. Antikolinergika. Aerobec och Autohaler spray 50 och 100 µg/dos Anoro Ellipta 55/22 µg/dos Airflusal Forspiro 50/250 och 50/500 µg/dos Vilanterol Umeklidinium Airomir 0,1mg/dos Autohaler spray 0,1mg/dos Airsalb 0,1mg/ dos

More information

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent

More information

Chronic Obstructive Pulmonary Disease (COPD) Admission Order Set

Chronic Obstructive Pulmonary Disease (COPD) Admission Order Set Patient Name: PHN: Page 1/1 Admit to Dr: Notified Consult: Dr: Family Dr: Precautions: Contact Droplet Enhanced Droplet Airborne - Reason: _ Code Status: Full Resuscitation or Consults: Reason: Dietician

More information

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.

More information

Asthma POEMs. Patient Orientated Evidence that Matters

Asthma POEMs. Patient Orientated Evidence that Matters ASTHMA POEMs Asthma POEMs Patient Orientated Evidence that Matters Developed by the Best Practice Advocacy Centre Level 8, 10 George Street PO Box 6032 Dunedin Phone 03 4775418 Fax 03 4772622 Acknowledgement

More information

Pulmonary Rehabilitation in Newark and Sherwood

Pulmonary Rehabilitation in Newark and Sherwood Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information

SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start using Seretide. This leaflet answers some

More information

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS Drug therapy 6 6.1 What is the role of bronchodilators in COPD? 52 SHORT-ACTING BETA AGONISTS 6.2 How do short-acting beta agonists work? 52 6.3 What are the indications for their use? 52 6.4 What is the

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin #902 March 6, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective March 6, 2015. Included in this bulletin: Regular Benefit Additions Special

More information

STAYING ASTHMA FREE. All you need to know about preventers. www.spacetobreathe.co.nz

STAYING ASTHMA FREE. All you need to know about preventers. www.spacetobreathe.co.nz STAYING ASTHMA FREE All you need to know about preventers www.spacetobreathe.co.nz HELPING YOUR CHILD BREATHE MORE EASILY GETTING TO KNOW THE PREVENTER What is a preventer? When do you use it? How do they

More information

Chronic obstructive pulmonary disease. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

Chronic obstructive pulmonary disease. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur Respir J 212; 4: 83 836 DOI: 1.1183/931936.225511 CopyrightßERS 212 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Paul W. Jones*, Dave Singh, Eric D. Bateman

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR)

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) Glucocorticoids, Inhaled Therapeutic Class Review (TCR) July 31, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease Karner C, Cates CJ This is a reprint of a Cochrane review, prepared

More information

CCHCS Care Guide: Asthma

CCHCS Care Guide: Asthma GOALS SHORTNESS OF BREATH, WHEEZE, COUGH NIGHT TIME AWAKENINGS ACTIVITY INTERFERENCE SABA* USE FOR SYMPTOM CONTROL FEV1* OR PEAK FLOW EXACERBATIONS REQUIRING ORAL STEROIDS < 2 DAYS / WEEK 2 TIMES / MONTH

More information

COPD. Julia Bott. Laura Cornish. Consultant Physiotherapist. Respiratory Specialist Physiotherapist Respiratory Care Team, Virgin Care, Chertsey

COPD. Julia Bott. Laura Cornish. Consultant Physiotherapist. Respiratory Specialist Physiotherapist Respiratory Care Team, Virgin Care, Chertsey COPD Julia Bott Consultant Physiotherapist Laura Cornish Respiratory Specialist Physiotherapist Respiratory Care Team, Virgin Care, Chertsey Acknowledgements Wayomi Perera, MD, MRCP Consultant in Respiratory

More information

Case study 42: Managing COPD exacerbations. June 2006. Results

Case study 42: Managing COPD exacerbations. June 2006. Results Results Case study 42: Managing COPD exacerbations June 2006 NPS is an independent, non-profit organisation for Quality Use of Medicines funded by the Australian Government Department of Health and Ageing.

More information

4 Pharmacological management

4 Pharmacological management 4 Pharmacological management The aim of asthma management is control of the disease. Control of asthma is defined as: no daytime symptoms no night time awakening due to asthma no need for rescue medication

More information

Diagnosis, Evaluation and Management of Adults and Children with Asthma

Diagnosis, Evaluation and Management of Adults and Children with Asthma Clinical Guideline for the Diagnosis, Evaluation and Management of Adults and Children with Asthma Color Key n Four Components of Asthma Care n Classifying Asthma Severity, Assessing Asthma Control and

More information

Seretide Diskus 50/100 Seretide Diskus 50/250 Seretide Diskus 50/500

Seretide Diskus 50/100 Seretide Diskus 50/250 Seretide Diskus 50/500 The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in November 2009 TITLE Salmeterol-Fluticasone Propionate (Salmeterol-FP) SCOPE Trade Name Salmeterol

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 12 Chronic obstructive pulmonary disease Anna Murphy Case study and questions Day 1 Mr LT, a 68-year-old man, attended his general practitioner s (GP s) surgery for a routine check-up. He had been diagnosed

More information

PLAN OF ACTION FOR. Physician Name Signature License Date

PLAN OF ACTION FOR. Physician Name Signature License Date PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes

More information

GUIDELINES FOR THE MANAGEMENT OF ADULT ASTHMA

GUIDELINES FOR THE MANAGEMENT OF ADULT ASTHMA GUIDELINES FOR THE MANAGEMENT OF ADULT ASTHMA Approved by the Winchester & Southampton District Prescribing Committee March 2008 SOUTHAMPTON RESPIRATORY GROUP March 2008 1 - CONTENTS ADULT ASTHMA GUIDELINE

More information

adrenoceptor agonists and the Olympic Games in Turin

adrenoceptor agonists and the Olympic Games in Turin Beta 2 adrenoceptor agonists and the Olympic Games in Turin 1. INTRODUCTION Article 4 of the World Anti-Doping Code refers to the Prohibited List as the international standard. This List, which came into

More information

Dear Provider: Sincerely,

Dear Provider: Sincerely, Asthma Toolkit Dear Provider: L.A. Care is pleased to present this updated asthma toolkit. Our goal is to promote the highest level of asthma care, based on the 2007 National Asthma Education and Prevention

More information

5. Treatment of Asthma in Children

5. Treatment of Asthma in Children Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

COPD. (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community

COPD. (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community COPD (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community Chronic Obstructive Pulmonary Disease (COPD) Definition Chronic obstructive pulmonary disease (COPD)

More information

Global Initiative for Chronic Obstructive Lung Disease

Global Initiative for Chronic Obstructive Lung Disease Global Initiative for Chronic Obstructive Lung Disease POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals REVISED 2011 Global Initiative for Chronic Obstructive

More information

Longitudinal Modeling of Lung Function in Respiratory Drug Development

Longitudinal Modeling of Lung Function in Respiratory Drug Development Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol MEDICATION GUIDE SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol SYMBICORT 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation

More information

Steroid treatment in cystic fibrosis

Steroid treatment in cystic fibrosis Steroid treatment in cystic fibrosis Factsheet August 2015 Steroid treatment in cystic fibrosis Introduction Steroids are used for their powerful antiinflammatory action and can be taken in a number of

More information

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and

More information

Steroid treatment in cystic fibrosis

Steroid treatment in cystic fibrosis Steroid treatment in cystic fibrosis Factsheet March 2013 Steroid treatment in cystic fibrosis Introduction This factsheet contains information on steroid treatment in cystic fibrosis, including the different

More information

NEWS NP S. Inside. Defining COPD. Is it COPD? National Prescribing Service Newsletter

NEWS NP S. Inside. Defining COPD. Is it COPD? National Prescribing Service Newsletter NP S NEWS National Prescribing Service Newsletter 5 1999 ISSN 1441-7421 Aug 99 Inside Bronchodilators and corticosteroids: Their use in COPD Give it up the best advice for COPD patients: NRT can help This

More information

POCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION

POCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION POCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION (for Adults and Children Older than 5 Years) A Pocket Guide for Physicians and Nurses Updated 2015 BASED ON THE GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND

More information

T HE ROLE OF THE PHARMACIST IN IMPROVING ASTHMA CARE NIH PUBLICATION NO. 95-3280 JULY 1995 NATIONAL INSTITUTES. National Heart, Lung,

T HE ROLE OF THE PHARMACIST IN IMPROVING ASTHMA CARE NIH PUBLICATION NO. 95-3280 JULY 1995 NATIONAL INSTITUTES. National Heart, Lung, T HE ROLE OF THE PHARMACIST IN IMPROVING ASTHMA CARE NIH PUBLICATION NO. 95-3280 JULY 1995 NATIONAL INSTITUTES OF HEALTH National Heart, Lung, and Blood Institute TABLE OF CONTENTS Preface.................................i

More information

Preventing Your Symptoms and Taking Your Medications

Preventing Your Symptoms and Taking Your Medications A Learning Tool for Patients and Their Families Preventing Your Symptoms and Taking Your Medications Understanding the self-cleaning mechanism of your airways Defining COPD, and learning about the main

More information

Initial U.S. Approval: 2013

Initial U.S. Approval: 2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA

More information

Workers Compensation Board of Nova Scotia

Workers Compensation Board of Nova Scotia Workers Compensation Board of Nova Scotia Work Safe, For Life Drugs listed in the WCB Special Authorization (SA) Formulary (see Appendix I) have specific criteria for coverage which must be met in order

More information

Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit

Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit July 26, 2014 Objectives Classify asthma by severity Prescribe

More information

The. Treating patients with COPD with medications

The. Treating patients with COPD with medications Treating patients with COPD with medications Gilbert E. D Alonzo Jr, MS, DO, FACOI; Fredric Jaffe, DO, FCCP; Samuel L. Krachman, DO SHUTTERSTOCK.COM The management treatment of chronic obstructive pulmonary

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine Meilan K Han, MD, MS Pulmonary Medicine R Van Harrison, PhD Medical Education Elisa B

More information

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization. Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should

More information

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,

More information

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts

More information

NHS FORTH VALLEY Guideline for the Management of Asthma

NHS FORTH VALLEY Guideline for the Management of Asthma NHS FORTH VALLEY Guideline for the Management of Asthma Date of First Issue 2004 Approved 18/09/2013 Current Issue Date 18/09/2013 Review Date 18/09/2016 Version 3.0 EQIA Yes 15/05/2009 Author / Contact

More information

Living Well With COPD Chronic Bronchitis and Emphysema

Living Well With COPD Chronic Bronchitis and Emphysema Living Well With COPD Chronic Bronchitis and Emphysema YOUR PATIENT GUIDE AMERICAN COLLEGE OF CHEST PHYSICIANS AND THE CHEST FOUNDATION Living Well With COPD Chronic Bronchitis and Emphysema YOUR PATIENT

More information

All Wales Prescription Writing Standards

All Wales Prescription Writing Standards All Wales Prescription Writing Standards These standards should be read in conjunction with completing the All Wales Medication Chart e- learning package, available on the Learning@NHSWales internet site

More information

Clinical guideline Published: 23 June 2010 nice.org.uk/guidance/cg101

Clinical guideline Published: 23 June 2010 nice.org.uk/guidance/cg101 Chronic obstructive pulmonary disease in over 16s: diagnosis and management Clinical guideline Published: 23 June 2010 nice.org.uk/guidance/cg101 NICE 2010. All rights reserved. Your responsibility The

More information

Respiratory medication use in Australia 2003 2013

Respiratory medication use in Australia 2003 2013 Respiratory medication use in Australia 2003 2013 Treatment of asthma and COPD ACAM Australian Centre for Airways disease Monitoring Respiratory medication use in Australia 2003 2013 Treatment of asthma

More information

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital Factors Associated with Underutilization of Inhalation Corticosteroids among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital By: Yohanes Ayele (B. Pharm) A thesis submitted to the School

More information

PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING

PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING FDA Briefing Document March 7, 213 NDA 24-275: fluticasone furoate and vilanterol inhalation powder for the long-term, maintenance treatment of airflow

More information

Asthma. Micah Long, MD

Asthma. Micah Long, MD Asthma Micah Long, MD Goals Define the two components of asthma. Describe the method of action and uses for: Steroids (inhaled and IV) Quick Beta Agonists (Nebs and MDIs) The "Others" Magnesium, Epi IM,

More information

Financial Disclosure. Pharmacy Technician Objectives: Definition: Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment

Financial Disclosure. Pharmacy Technician Objectives: Definition: Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment Roger Hefflinger, Pharm.D. Clinical Associate Professor Family Medicine Residency of Idaho Idaho State University College of Pharmacy Financial

More information

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation

More information

Medicines Use Review Supporting Information for Asthma Patients

Medicines Use Review Supporting Information for Asthma Patients Medicines Use Review Supporting Information for Asthma Patients What is asthma? Asthma is a chronic inflammatory disorder of the airways. The inflammation causes an associated increase in airway hyper-responsiveness,

More information

Asthma & COPD Medication List

Asthma & COPD Medication List Asthma & COPD Medication List LONG-TERM CONTROL MEDICATIONS (used for prevention / control of asthma, NOT treatment of acute exacerbations) a. INHALED CORTICOSTEROIDS (ICS) Drug of choice for all levels

More information

INSIDE: Your Asthma Journey Step By Step

INSIDE: Your Asthma Journey Step By Step 8229 Boone Blvd. Suite 260 Vienna, VA 22182 800.878.4403 www.aanma.org info@aanma.org Understanding Asthma: Building Blocks For Better Breathing Allergy & Asthma Today Special Edition is published by Allergy

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

salmeterol xinafoate/fluticasone propionate dry powder for inhalation salmeterol xinafoate/fluticasone propionate inhalation aerosol

salmeterol xinafoate/fluticasone propionate dry powder for inhalation salmeterol xinafoate/fluticasone propionate inhalation aerosol Pr ADVAIR DISKUS salmeterol xinafoate/fluticasone propionate dry powder for inhalation Pr ADVAIR 100 DISKUS 50 mcg salmeterol (as the xinafoate salt) and 100 mcg fluticasone propionate Pr ADVAIR 250 DISKUS

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

COST COMPARISON CHARTS July 2015

COST COMPARISON CHARTS July 2015 REGIONAL DRUG AND THERAPEUTICS CENTRE (NEWCASTLE) COST COMPARISON CHARTS July 2015 INTRODUCTION 16/17 Framlington Place Newcastle upon Tyne NE2 4AB Charts are organised by BNF classification and show comparative

More information

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations ORIGINAL RESEARCH Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations Kai-Michael Beeh 1 Bettina Hederer 2 Thomas Glaab 2 Achim Müller 2 Maureen

More information

understanding the professional guidelines

understanding the professional guidelines SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.

More information

Medications prescribed for people with obstructive airways disease Antibiotics and inhaled corticosteroids

Medications prescribed for people with obstructive airways disease Antibiotics and inhaled corticosteroids Medications prescribed for people with obstructive airways disease Antibiotics and inhaled corticosteroids Medications prescribed for people with obstructive airways disease Antibiotics and inhaled corticosteroids

More information

BEST PRACTICE EVIDENCE BASED GUIDELINE

BEST PRACTICE EVIDENCE BASED GUIDELINE BEST PRACTICE EVIDENCE BASED GUIDELINE MANAGEMENT OF ASTHMA IN CHILDREN AGED 1-15 YEARS. 2005 PAEDIATRIC SOCIETY OF NEW ZEALAND HEALTH OF OUR CHILDREN: WEALTH OF OUR NATION WWW.PAEDIATRICS.ORG.NZ Page

More information

CURRICULUM VITAE KIRK GEORGE VOELKER, M.D.

CURRICULUM VITAE KIRK GEORGE VOELKER, M.D. PERSONAL INFORMATION DATE OF BIRTH December 29, 1961 PLACE OF BIRTH OFFICE ADDRESS E-MAIL Buffalo, NY. 1537 State St. 34236 (941) 330-1696 Dr.Voelker@comcast.net ACADEMIC RECORD UNDERGRADUATE MEDICAL SCHOOL

More information

Corticosteroids for COPD Exacerbation

Corticosteroids for COPD Exacerbation PL Detail-Document #290801 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER August 2013 Corticosteroids

More information

Standardizing the measurement of drug exposure

Standardizing the measurement of drug exposure Standardizing the measurement of drug exposure The ability to determine drug exposure in real-world clinical practice enables important insights for the optimal use of medicines and healthcare resources.

More information

- Canine Chronic Bronchitis cannot be cured, but can be controlled

- Canine Chronic Bronchitis cannot be cured, but can be controlled MD-096A-0211 1 2 - The symptoms of asthma can mimic other diseases such as heartworm, pneumonia and congestive heart failure (Padrid, Use of Inhaled Medications to Treat Respiratory Diseases in Dogs and

More information

Rolenium 50 microgram/250 microgram/dose inhalation powder, pre-dispensed Rolenium 50 microgram/500 microgram/dose inhalation powder, pre-dispensed

Rolenium 50 microgram/250 microgram/dose inhalation powder, pre-dispensed Rolenium 50 microgram/500 microgram/dose inhalation powder, pre-dispensed 1. NAME OF THE MEDICINAL PRODUCT Rolenium 50 microgram/250 microgram/dose inhalation powder, pre-dispensed Rolenium 50 microgram/500 microgram/dose inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE

More information

The Respiratory Therapist As Disease Manager

The Respiratory Therapist As Disease Manager The Respiratory Therapist As Disease Manager Bill Pruitt, MBA, RRT, CPFT, AE-C, FAARC Director of Clinical Education, Senior Instructor Cardiorespiratory Care University of South Alabama Mobile Alabama

More information

Management of Asthma

Management of Asthma Federal Bureau of Prisons Clinical Practice Guidelines May 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant

More information

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) FOR ORAL INHALATION USE Initial U.S. Approval: 2013

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) FOR ORAL INHALATION USE Initial U.S. Approval: 2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use the ANORO ELLIPTA inhaler safely and effectively. See full prescribing information for ANORO ELLIPTA.

More information

Vectura Group plc Annual Report and Accounts 2010/11

Vectura Group plc Annual Report and Accounts 2010/11 Vectura Group plc Annual Report and Accounts 2010/11 Contents 01 Highlights 2010/11 02 Chairman and Chief Executive s report 04 Financial review 05 Business review: overview 06 core purpose, values and

More information